Investor Relations

Press Releases

Date Title and Summary View
Toggle Summary The Cancer Genome Atlas (TCGA) Study Supports Power of Subtyping Breast Cancer by PAM50
The Cancer Genome Atlas (TCGA) Study Supports Power of Subtyping Breast Cancer by PAM50   Online Publication in Journal Nature Shows PAM50 Potentially Simplifies Underlying Tumor Biology SEATTLE, Wash. | September 24, 2012 – On September 23, researchers published online in the journal Nature a
View HTML
Toggle Summary The Cancer Genome Atlas (TCGA) Study Supports Power of Subtyping Breast Cancer by PAM50
The Cancer Genome Atlas (TCGA) Study Supports Power of Subtyping Breast Cancer by PAM50   Online Publication in Journal Nature Shows PAM50 Potentially Simplifies Underlying Tumor Biology SEATTLE, Wash. | September 24, 2012 – On September 23, researchers published online in the journal Nature a
View HTML
Toggle Summary NanoString Technologies Names Dale R. Levitzke Vice President of Global Sales for Life Sciences
NanoString Technologies Names Dale R. Levitzke Vice President of Global Sales for Life Sciences   SEATTLE, Wash. | August 7, 2012 – NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the
View HTML
Toggle Summary NanoString Technologies Appoints Senior Financial Executive Greg Norden to Board of Directors
NanoString Technologies Appoints Senior Financial Executive Greg Norden to Board of Directors   Seattle, WA | July 18, 2012 – NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the
View HTML
Toggle Summary NanoString Technologies Names Bruce Seeley Senior Vice President & General Manager, Diagnostics
NanoString Technologies Names Bruce Seeley Senior Vice President & General Manager, Diagnostics   SEATTLE, Wash. | May 29, 2012 – NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the
View HTML
Toggle Summary NanoString Initiates Second Clinical Validation Study for Breast Cancer Assay
NanoString Initiates Second Clinical Validation Study for Breast Cancer Assay   Study to Evaluate the Ability of PAM50 to Estimate Prognosis in Women with Early-Stage Breast Cancer SEATTLE, Wash. | May 16, 2012 – NanoString Technologies, Inc., a privately held provider of life science tools for
View HTML
Toggle Summary NanoString Technologies Names Joseph M. Beechem Senior Vice President of R&D
NanoString Technologies Names Joseph M. Beechem Senior Vice President of R&D   SEATTLE, Wash. | April 9, 2012   -  NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the appointment of
View HTML
Toggle Summary Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies
Oxford Finance and Silicon Valley Bank Provide $15 Million Senior Credit Facility to NanoString Technologies   Alexandria, VA | April 3, 2012   -  Oxford Finance LLC (“Oxford”), a specialty finance firm that provides senior debt to life sciences and healthcare services companies, today announced a
View HTML
Toggle Summary NanoString Introduces Three New Products at AACR Annual Meeting
NanoString Introduces Three New Products at AACR Annual Meeting   New Offerings Accelerate the Completion of Studies and Expand FFPE Analysis Portfolio SEATTLE, Wash. | March 30, 2012   -  NanoString Technologies, Inc., a privately held provider of life science tools for translational research and
View HTML
Toggle Summary NanoString Technologies Announces Positive Results from First Validation Study of PAM50-based Breast Cancer Assay
NanoString Technologies Announces Positive Results from First Validation Study of PAM50-based Breast Cancer Assay   Study Establishes Prognostic Performance of NanoString's First Diagnostic Product, Demonstrates NanoString's Assay Provides Significantly More Prognostic Information and
View HTML